147 results about "Lung Inflammations" patented technology

Disclosed is the use of an antagonist of Interleukin 1 receptor type 1 (IL-1R1) for the manufacture of a medicament treating, preventing or suppressing lung inflammation or a respiratory disease. In some embodiments of the described invention, the medicament is for local administration to pulmonary tissue. Also disclosed are methods for treating lung inflammation or a respiratory disease.

Described herein are methods and compositions for treatment of inflammation, such as inflammation in lung and / or airway tissue, including asthma Innate lymphoid cells (ILCs), such as type 2 ILC2s, are herein described as capable of IL-33 signaling activation, leading to airway hyperresponsiveness (AHR) and inflammation. Further described is the hereto unknown discovery that ICOS-ligand is expressed in ILC2s, that ICOS binding of ICOS to ICOS-ligand is required for its function in ILC2s, and that while IL-33 treatment induces AHR in control mice, IL-33 cannot induce AHR in mice receiving treatment via anti-ICOS-ligand antibodies. These results suggest new methods and compositions targeting ICOS and ICOS-ligand, such as dual specific antibodies that recognize ICOS and ICOS-ligand, an expression profile unique to ILC2s.

Methods of treating, reducing, or preventing lung infections or lung inflammation include identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Treatment of cystic fibrosis lung infections, COPD lung infections, inflammation of the lungs in these patient populations, and lung scarring in these patient populations is also described.

The present invention relates to pharmaceutical kits and methods to treat lung inflammation and redox imbalance in human cystic fibrosis patients using pharmaceutical compositions containing N-acetylcysteine (NAC), pharmaceutically acceptable salts of N-acetylcysteine, or N-acetylcysteine derivatives. In phase I studies, treatment with oral NAC at a dose of from about 1800 mg / day to about 3000 mg / day for a period of 4 weeks produced significant positive effects, namely, it decreased absolute numbers of white blood cells and neutrophils in the sputum and produced concomitant decreases in sputum neutrophil elastase specific activity and sputum interleukin-8 levels, suggesting an amelioration of lung inflammation in the patients. These effects were associated with an increased total GSH level in whole blood as well increased staining for reduced GSH in blood neutrophils, both of which reflect an amelioration of the redox imbalance in the patients. In ongoing phase II studies, oral NAC at a dose of about 2700 mg / day administered in double-blind manner for 12 weeks showed excellent safety and significantly decreased white blood cells in sputum as compared to placebo.

The invention discloses Lactobacillus reuteri capable of relieving atopic asthma Th2 reaction and application of Lactobacillus reuteri and belongs to the technical fields of microorganisms and medicine. The Lactobacillus reuteri has an atopic asthma relieving function, specifically reflected as follows: (1) significantly reducing lung inflammation reaction of atopic asthma mice; (2) remarkably inhibiting production of total immunoglobulin IgE in serum of the atopic asthma mice; (3) significantly decreasing the content of IL-5 in lungs of atopic asthma mice; (4) significantly decreasing the content of IL-13 in lungs of atopic asthma mice; and (5) significantly raising the content of propionic acid in intestines of atopic asthma mice. Therefore, the Lactobacillus reuteri has great application prospects in preparation of a product for preventing and / or treating atopic asthma.

This invention relates to a sealed container containing a powder formulation comprising a dehydroepiandrosterone, its analogue(s) or salt(s) by itself or with a pharmaceutically or veterinarily acceptable carrier or diluent, and having a particle size of about 0.1 μm to about 100 μm. The formulation can be used to treat or prevent asthma, chronic obstructive pulmonary disease, lung inflammation, and other respiratory diseases or conditions. The formulation may be prepared by jet milling, and may be delivered through the respiratory tract or other routes using a nebulizer. The sealed container is provided in a device and / or a therapeutic kit.

Compositions and methods for the treatment of inflammation are provided.

The present invention relates to a Chinese herbal composition for treating bacterial lipopolysaccharide-induced diseases. The composition is extracted from a mixture of Huang Qui, Huanglian and Dauhuang. The composition is used for treating a lung inflammation and a hypotension.

The invention relates to compounds of formula (I):or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, which are inhibitors of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.

The present disclosure relates to compounds of formula (I):which are inhibitors of p38 mitogen-activated protein kinase enzymes, particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD

The invention provides three kinds of radix pseudostellariae extracts and applications thereof to preparation of drugs for treating lung-qi deficiency symptom related diseases. The three kinds of radix pseudostellariae extracts can suppress lung inflammation reactions, benefit qi and promote the production of body fluid, enhance resistance, recover immunologic balance, improve lung functions and eliminate and relieve such lung-qi deficiency symptoms as lack of strength, palpitation and shortness of breath. An improvement of lung-qi deficiency has great significance to control of frequently occurring and intractable lung diseases with the characteristic of recurrent attack.

Evidence is presented that inflammation and injury involves activation of xanthine oxidoreductase (XOR) in the newly recruited mononuclear phagocytes (MNP). XOR has been shown to be increased predominantly in the MNP that increase rapidly in the lungs of rats that develop acute lung injury (ALI) following intratracheal cytokine insufflation. XOR was recovered from the MNP largely converted to its oxygen radical generating, reversible O-form, and alveolar MNP exhibited increased oxidative stress as evidenced by increased nitrotyrosine staining. Cytokine insufflation also increased alveolar cell apoptosis. A functional role for XOR in cytokine induced inflammation was demonstrated. Tungsten and allopurinol decreased MNP XOR induction, nitrotyrosine staining, inflammatory cell infiltration, and alveolar cell apoptosis. Transfer of control or allopurinol treated MNP into rat lungs and confirmed a specific role for MNP XOR in promoting lung inflammation. These data indicate that XOR can contribute to lung inflammation by its expression and conversion in a highly mobile inflammatory cell population.

The invention relates to health protection tea and a preparation method thereof, in particular to health protection tea for treating chronic bronchitis and a preparation method thereof. The incidence rate of chronic bronchitis in middle-aged and old-aged populations is high, and chronic bronchitis is a common respiratory disease. In recent years, along with the aggravation of environmental pollution and the declination of air quality, people with chronic bronchitis have the development tendency of young change. The health protection tea for treating chronic bronchitis is guided by the theories of traditional Chinese medicine by combining with the tea drinking culture of China and is prepared from the raw materials of honeysuckle, apricot kernels, dried pineapple, loquat leaves, walnut kernels, licorice roots, Chinese mugwort leaves, ginger slices, red dates, dwarf lilyturf tuber, lily, dandelion, peppermint, cape jasmine, rhizoma anemarrhenae, fritillaria, tea leaves and honey through refining. The health protection tea can effectively eliminate lung inflammation, promote blood circulation, dissipate stasis, relieve a cough, disperse the lungs, promote the secretion of saliva and regulate qi, has outstanding curative effects on chronic bronchitis and can be dunk for a long time without any adverse drug resistance reaction and side effect.

The invention relates to the technical field of medicine preparations, in particular to a medicine composition with tiotropium bromide and formoterol, application of the medicine composition and a preparation. The medicine composition comprises the tiotropium bromide or pharmaceutically acceptable salt of the tiotropium bromide and the formoterol or pharmaceutically acceptable salt of the formoterol. The medicine composition with the tiotropium bromide and the formoterol is applied to preparing medicine for treating respiratory and lung inflammatory diseases. The medicine composition is preferably a tiotropium bromide and formoterol composition with synergistic additive effects. The medicine composition, the application and the preparation have the advantages that as proved by pharmacodynamic experiments, the synergistic additive effects can be realized by the tiotropium bromide and the formoterol which are jointly applied, and accordingly bronchiectasis can be forcefully and quickly realized; the medicine composition and the preparation are used for treating the respiratory and lung inflammatory diseases, and preferably used for treating dyspnea such as bronchial asthma and chronic obstructive pulmonary diseases (COPD) due to bronchial constriction.

The invention discloses lactobacillus reuteri capable of alleviating allergic asthma and application thereof and belongs to the technical field of medicines. The lactobacillus reuteri has an effect ofrelieving allergic asthma, which is embodied by: (1) significantly reducing lung inflammation in mice with allergic asthma; (2) significantly inhibiting the generation of dust mite specific immunoglobulin IgG1 in serum of allergic asthma mice; (3) significantly reduced the contents of IL-5 and IL-13 in alveolar lavage fluid of mice with allergic asthma; (4) significantly reducing the content of IL-17A in alveolar lavage fluid of mice with allergic asthma, and thus the lactobacillus reuteri has great application prospects in the preparation of products for preventing and / or treating allergic asthma.

Disclosed herein are compounds, compositions and methods for modulating the expression of TARC in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of TARC, airway hyperresponsiveness, and / or pulmonary inflammation.

The invention provides a low molecular weight carrageenan oligosaccharide. The low molecular weight carrageenan oligosaccharide is formed by alternative connections of 1,3-beta-D galactose and1,4-alpha-D galactose, and has a weight-average molecular weight of 1-3 kD and a structural formula of G4S-[A-G4S] <n->, wherein n is 1-7, and a sulfate radical content is 8-12%. The carrageenan oligosaccharide can not only oppose infection of Influenza A virus subtype H1N1 in vitro, but also substantially mitigate mice lung inflammation caused by virus infection, reduce mortality and prolong survival time. The carrageenan oligosaccharide of the invention is from sea red alga, has many advantages of wide source, low toxicity and high efficiency, can well inhibit infection of Influenza A virus in vitro and in vivo and has wide market application prospect in controlling Influenza A virus.

This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.

The invention relates to rehmanniae radix oligosaccharides, the method for preparing the same, and its application. The method comprises taking rehmanniae radix medicinal materials as raw material, extracting with and getting rehmanniae radix total sugar, separating with silica gel column and getting the oligosaccharides, mainly comprising stachyose, and. The content is more than 60%. It is demonstrated by pharmacodynamics experiment that the oligosaccharides can inhibit rat lung inflammation induced by lipopolysaccharide of coli bacillus, and can be used to prepare drug treating chronic obstructive pulmonary disease.

The invention relates to application of dendrobium officinale polysaccharides in preparation of harm-reducing cigarettes. Harm reduction means reducing risks of lung inflammation caused by smoking. The harm-reducing cigarettes are prepared by dissolving the dendrobium officinale polysaccharides by utilizing water, evenly spraying the dendrobium officinale polysaccharides on cut tobaccos, naturally airing the cut tobaccos, and then rolling the cigarettes according to regular cigarette rolling technology. The application of dendrobium officinale polysaccharides in preparation of harm-reducing cigarettes can reduce the occurrence rate of lung inflammation caused by smoking and reduce expression of kinase beta (IKKbeta) of a lung tissue nuclear factor Kappa B(NF-kB) inhibitor caused by smoking.

The invention provides a nuclear microporous membrane for an atomizer plate. The nuclear microporous membrane comprises a microporous area and an immobilized area, wherein the microporous area is arranged in the middle and is provided with conical micropores; and the immobilized area is arranged on the periphery of the microporous area. The nuclear microporous membrane provided by the invention has the beneficial effects that 1) particle size is controlled by pores, so that most drug particles can directly reach pulmonary alveoli, and can act on lung inflammation sites through effects of gravity deposition and dispersion deposition; 2) pore pattern of the nuclear microporous membrane can be optionally adjusted, so that a purpose of conducting passive targeted therapy can be achieved; 3) anatomizing dosage is controlled by the density of pores of the nuclear microporous membrane; therefore, drug dosage can be adjusted, and it is possible to conduct large-dose administration within a short time; 4) ultra-high frequency ultrasonic means can be avoided, so that a circumstance that partial drugs become invalid due to too high temperature of a vibrating plate can be prevented; and 5) large-dose administration can be achieved without the assistance of high-power ultrasonic wave.

The invention discloses application of ginkgo biflavonoids to preparation of a medicine for preventing and treating asthma. The ginkgo biflavonoids are at least one of 7-demethylated biflavones, ginkgetin, sciadopitysin, and isoginkgetin. The invention discloses a medicinal composition for preventing and treating the asthma, the composition comprises ginkgo biflavonoids, and further comprises at least one of radix glycyrrhizae, white mulberry root-bark and semen armeniacae amarum. The invention further discloses a pharmaceutical composition formed by mixing ginkgo biflavonoids and a pharmaceutically acceptable excipient, and the mass percent of ginkgo biflavonoids is greater than and equal to 2.5%. The ginkgo biflavonoids can inhibit the recruitment of inflammatory cells in lungs, reduce the expression of inflammatory factors in the lungs, and lower the expression of PI3K-related proteins in inflammation pathways, and are free of obvious toxic or side effects and safe and reliable after being taken for a long term.

The invention relates to a pharmaceutical composition for treating bronchitis and asthma. The pharmaceutical composition is prepared from the following components by weight: 40 to 60 parts of aster root, 40 to 60 parts of dandelion, 25 to 35 parts of stemona root, 25 to 35 parts of anemarrhena, 20 to 30 parts of tendrilleaf fritillary bulb, 10 to 20 parts of ephedra stem, 10 to 20 parts of common andrographis herb, 10 to 20 parts of isatis root, 3 to 8 parts of LagotisclarkeiHook.F., 3 to 8 parts of borneol and 3 to 8 parts of dwarf lilyturf root. The ministerial drugs of the pharmaceutical composition are capable of clearing heat, removing toxins, eliminating phlegm, dissipating binds, generating body fluid and moisturizing dryness, thereby eliminating inflammations of bronchi and the lung, and capable of tonifying the spleen and the kidney, thereby eliminating the symptom of difficulty in breathing; the adjuvant and conductant drugs are used for maintenance and protection of the respiratory system and for basis consolidation; drugs of the pharmaceutical composition are compatible and synergistic, so inflammations are eliminated, and the adjuvant and conductant drugs are cooperatively used for alleviation of toxicity and virulence of drugs; and the pharmaceutical composition is used for treating a series of symptoms caused by bronchitis and asthma.

The invention provides new application of erucic acid in preparing a medicine for preventing or treating vaccinum influenzae vivum. The invention also provides the medicine for preventing or treatingvaccinum influenzae vivum. The medicine is prepared from the active ingredient erucic acid. The inventor finds that the erucic acid has remarkable inhibitory activity on vaccinum influenzae vivum replicated and mediated inflammatory reaction. A liquid chip technology is adopted to prove that the erucic acid can remarkably inhibit the abnormal expression of an H1N1 virus infected A549 cell inflammatory factor and is in a dose-dependent relationship; an immunoblotting method is adopted to prove that the erucic acid can inhibit activation of a host inflammation-associated signal path and is in adose-dependent relationship; Annexin V-FITC / PI double-tagging flow cytometry is adopted to prove that the erucic acid can remarkably inhibit apoptotic lesion of a flue H1N1 induced host cell and is ina dose-dependent relationship. Animal experiments prove that the erucic acid can remarkably inhibit lung inflammation and apoptotic lesion induced by vaccinum influenzae vivum H1N1, and the survivaltime of rats is effectively prolonged.

This invention provides compounds of Formulae (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA), and (IIIB); pharmaceutically acceptable salts and solvates thereof; and compositions thereof. This invention further provides methods for treating a disease, including but not limited to, liver disease or an abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); a malignant or benign tumor of the lung, liver, gall bladder, bile duct or digestive tract; an intra- or extra-hepatic bile duct disease; a disorder of lipoprotein; a lipid-and-metabolic disorder; cirrhosis; fibrosis; a disorder of glucose metabolism; a cardiovascular or related vascular disorder; a disease resulting from steatosis, fibrosis, or cirrhosis; a disease associated with increased inflammation (such as hepatic inflammation or pulmonary inflammation); hepatocyte ballooning; a peroxisome proliferator activated receptor-associated disorder; an ATP citrate lyase disorder; an acetyl-coenzyme A carboxylase disorder; obesity; pancreatitis; or renal disease.

The present invention discloses a use of cholesterol-modified HuR interference siRNA in preparation of drugs for treating acute lung injury caused by sepsis. According to the present invention, the related HuR interference siRNA is an artificially-synthesized and cholesterol-modified small nucleic acid drug; with intravenous administration, results show that the HuR siRNA can be richly distributed in lung tissue, enter lung cells, inhibit a plurality of 3'-UTR of mRNA of inflammatory factors having HuR binding sites, and promote TNFalpha RNA degradation so as to inhibit acute lung injury induced by bacterial lipopolysaccharide (LPS), wherein TNFalpha expression can be inhibited; and the small nucleic acid drug provides significant release effects for lung inflammation, is applicable for intravenous administration, inhalation administration or intratracheal administration, and is the small nucleic acid drug having application values and prospects and provided for treating acute lung injury under the premise of lack of effective and related acute lung injury treatment nucleic acid drugs in the prior art.